Nvidia has dominated the AI narrative in the stock market, captivating investors and the media after soaring 2,190% over the ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Polaris Capital Management, an investment management company, released its third quarter 2024 investor letter. A copy of the ...

Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $92.57 which represents a slight increase of $1.48 or 1.62% from the prior close of $91.09. The stock opened at $90.92 and ...

在激烈的生物医药竞争中，Assembly Biosciences（纳斯达克代码：ASMB）最近传出了振奋人心的消息。该公司专注于开发针对严重病毒性疾病的创新疗法，并于19日宣布获得了巨头吉利德科学（Gilead Sciences）2010万美元的股权投资。这笔投资不仅提升了吉利德对Assembly Bio的持股比例至29.9%，同时还包括1000万美元的加速资金，用于推动新型抗病毒疗法的研发。

Gilead Sciences will no longer provide four HIV medicines for free as part of a patient assistance program starting at the ...

“科研圈日报”主要关注科研圈与研究者个体、科研圈与更广阔的社会环境之间的重要互动。点击 这里 可以查看往期内容。· 科学突破《科学》公布 2024 年度十大突破，SpaceX“筷子夹火箭”入选，长效艾滋病预防药物位列榜首图片来源：SpaceX当地时间 ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor ...

01 吉利德科学公司宣布，美国FDA已授予Trodelvy突破性疗法认定，用于治疗接受铂类化疗后疾病进展的广泛期小细胞肺癌 (ES-SCLC)成人患者。 04 目前，Trodelvy已在超过50个国家和地区获批，用于治疗经治转移性三阴性乳腺癌 ...

In a report released yesterday, Courtney Breen from Bernstein maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...

Gilead Sciences, Inc. has announced that Trodelvy (sacituzumab govitecan-hziy) has received Breakthrough Therapy Designation ...